Silver Book Fact

Drug-resistant MRSA expensive to treat

As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.

Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso. Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2009; 54(1): 109-15. http://aac.asm.org/content/54/1/109.full

Reference

Title
Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria
Publication
Antimicrob Agents Chemother
Publication Date
2009
Authors
Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso
Volume & Issue
Volume 54, Issue 1
Pages
109-15
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Source of 99,000 annual deaths from HAIs
    Of the 99,000 annual deaths from HAIs: 35,967 are from pneumonia 30,665 are from bloodstream infections 13,088 are from urinary tract infections 8,205 are from surgical site infections; and 11,062 are from infections at other…  
  • 75% of c. diff infections start in places like nursing homes and physician offices
    75% of clostridium difficile (C. difficile) infections, a common HAI, start in places like nursing homes and physician offices.  
  • Sepsis accounts for 17% of in-hospital deaths
    In 2008, only 2% of hospitalization were for sepsis/septicemia, yet they made up 17% of in-hospital deaths.  
  • Primary sources of HAIs
    Around 2/3 of all HAIs are central-line associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia. Surgical site infections and Clostridium difficile (C. difficile) are also common HAIs.  
  • Comorbidities and hospitalization higher with HAIs
    Patients with HAIs have more comorbidities (2.8 vs. 1.9) and in-hospital mortality (9% vs. 1.5%), compared to all other hospitalized patients.